SG Americas Securities LLC grew its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 39.1% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 29,341 shares of the company's stock after acquiring an additional 8,240 shares during the period. SG Americas Securities LLC's holdings in CRISPR Therapeutics were worth $998,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in CRSP. Wood Tarver Financial Group LLC purchased a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $30,000. Ameriflex Group Inc. purchased a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $36,000. NBC Securities Inc. increased its stake in CRISPR Therapeutics by 156,300.0% during the 1st quarter. NBC Securities Inc. now owns 1,564 shares of the company's stock worth $53,000 after buying an additional 1,563 shares during the period. GF Fund Management CO. LTD. purchased a new stake in CRISPR Therapeutics during the 4th quarter worth approximately $71,000. Finally, First Horizon Advisors Inc. increased its stake in CRISPR Therapeutics by 33.4% during the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock worth $80,000 after buying an additional 511 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, insider Naimish Patel sold 3,932 shares of the stock in a transaction on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider now owns 6,068 shares in the company, valued at $218,083.92. This represents a 39.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is owned by company insiders.
Analysts Set New Price Targets
Several brokerages recently weighed in on CRSP. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of CRISPR Therapeutics in a research note on Wednesday, February 19th. Needham & Company LLC reiterated a "buy" rating and set a $81.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, May 20th. The Goldman Sachs Group lowered their price target on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. JMP Securities reiterated a "market outperform" rating and set a $86.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, May 21st. Finally, Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $69.53.
Get Our Latest Analysis on CRSP
CRISPR Therapeutics Price Performance
Shares of CRISPR Therapeutics stock traded up $1.24 during trading hours on Thursday, hitting $44.43. The company had a trading volume of 5,694,335 shares, compared to its average volume of 1,782,951. The company's 50-day moving average is $38.52 and its two-hundred day moving average is $40.72. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $63.68. The company has a market cap of $3.84 billion, a P/E ratio of -9.83 and a beta of 1.75.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The company's quarterly revenue was up 71.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.43) EPS. Sell-side analysts expect that CRISPR Therapeutics AG will post -5.16 EPS for the current year.
About CRISPR Therapeutics
(
Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Recommended Stories
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
